![GettyImages-479562442-600x398](https://medphanut.com/wp-content/uploads/2024/06/GettyImages-479562442-600x398-600x381.jpg)
Alumis’s lead drug candidate blocks TYK2, an inflammation target that’s already addressed by Sotyktu, a Bristol Myers Squibb drug approved for plaque psoriasis. Alumis plans to begin two Phase 3 tests in this indication later this year.
The post Inflammation Biotech Alumis Trims IPO Plans But Still Raises $250M for Clinical Trials appeared first on MedCity News.